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STAT1North American eastern equine encephalitis virus (NA-EEEV) strains cause high mortality in humans,
whereas South American strains (SA-EEEV) are typically avirulent. To clarify mechanisms of SA-EEEV
attenuation, we compared mouse-attenuated BeAr436087 SA-EEEV, considered an EEEV vaccine candidate,
with mouse-virulent NA-EEEV strain, FL93-939. Although attenuated, BeAr436087 initially replicated more
efﬁciently than FL93-939 in lymphoid and other tissues, inducing systemic IFN-α/β release, whereas FL93-
939 induced little. BeAr436087 was more virulent than FL93-939 in IFN-α/β-deﬁcient mice, conﬁrming
that type I IFN responses determined attenuation, but the viruses were similarly sensitive to IFN-α/β
priming in vitro. Infection with BeAr436087 protected against FL93-939 disease/death, even when given
8 h afterward, suggesting that the environment produced by BeAr436087 infection attenuated FL93-939.
We conclude that avoidance of IFN-α/β induction is a major virulence factor for FL93-939. Furthermore,
BeAr436087 could be used for vaccination and therapeutic treatment in the event of exposure to NA-EEEV
during a bioterrorism attack.© 2009 Elsevier Inc. All rights reserved.Introduction
Eastern equine encephalitis virus (EEEV) is a positive-sense,
single-stranded RNA virus belonging to the genus Alphavirus, family
Togaviridae. Areas where EEEV is endemic range from the north-
eastern through the southeastern United States and into Latin and
South America. EEEV is the sole virus species in the EEE antigenic
complex, but phylogenetic trees have revealed distinct North Amer-
ican and South American lineages (Weaver et al., 1999). North
American EEEV (NA-EEEV) isolates are highly conserved, differing
by less than 2% in their nucleotide sequences over many years and a
large geographic range (Weaver et al., 1999; Armstrong et al., 2008;
Young et al., 2008). In contrast, South American EEEV (SA-EEEV)
isolates evolve more rapidly and at least three genotypes can be
delineated that differ by up to 25% in their nucleotide sequence
(Kondig et al., 2007; Weaver et al., 1999).
The case to fatality rate for NA-EEEV infection of humans is 30–
70%, with 35–80% of survivors suffering permanent, severe neurolo-
gical impairments (Smith et al., 1997). In addition, NA-EEEV is also
lethal in up to 90% of recognized equine cases (Rua-Domenech et al.,
1999). The severity of human disease, coupled with the lack of
licensed human vaccines or antiviral therapies, makes NA-EEEV all rights reserved.threat as both an emerging infectious disease and a biowarfare/
terrorism (BWT) agent. SA-EEEV strains, on the other hand, are
generally avirulent in humans and only occasionally cause disease in
equines. Only two human cases of SA-EEEV encephalitis have been
reported (Alice, 1956; Corniou et al., 1972), although seroprevalence
associated with exposure can be as high as 25–66% (Causey and
Theiler, 1958; Aguilar et al., 2005, 2007a). Although the differential
virulence of NA versus SA strains in humans remains uncertain,
correlation with sensitivity to the interferon alpha/beta (IFN-α/β) or
gamma (IFN-γ)-induced antiviral state has been demonstrated in
Vero cells (Aguilar et al., 2005, 2008a).
In mice, the majority of EEEV strains exhibit a similar degree of
virulence, with high mortality (Aguilar et al., 2005; Gardner et al.,
2008; Vogel et al., 2005). However, SA-EEEV strain, BeAr436087
(Weaver et al., 1999), is relatively attenuated in mice compared with
other strains, causing no mortality following subcutaneous admin-
istration to adult animals (Aguilar et al., 2005, 2008a). Chimeric
viruses, in which the non-structural or structural protein encoding
regions of the BeAr436087 genome were exchanged with those of
virulent NA-EEEV isolate, FL93-939, implicated both regions in the
attenuated phenotype (Aguilar et al., 2008a). Furthermore,
BeAr436087 immunizes mice against subsequent challenge with a
virulent NA-EEEV strain (Wang et al., 2007) and, thus, has potential
for use as a live-attenuated vaccine against virulent NA-EEEV
strains.
In an attempt to determine correlates of human- and mouse-
attenuation of the SA-EEEV BeAr436087 strain that could be applied
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the mechanisms underlying the virulence of NA-EEEV strains, we
have performed detailed pathogenesis studies in mice comparing the
association of replication potential and type I IFN induction/
sensitivity with disease pathogenesis of BeAr436087 virus with
that of the human- and mouse-virulent NA-EEEV FL93-939 strain.
Surprisingly, in the absence of overt disease, BeAr436087 virus
infection resulted in earlier and higher level virus replication in
lymphoid and other non-neural tissues of mice than the uniformly
fatal FL93-939 virus infection. Attenuation correlated with induction
of high levels of IFN-α/β in the serum of BeAr436087-infected mice,
while little or no IFN-α/β could be detected in sera from FL93-939-
infected animals. The difference in serum IFN-α/β was functionally
signiﬁcant as phosphorylation of the IFN signaling-activated tran-
scription factor STAT1 was greater in the brains of BeAr436087-
infected mice, a tissue associated with EEEV disease. Further
supportive of a role for the IFN-α/β response in the attenuation of
BeAr436087, this virus was signiﬁcantly more virulent than FL93-939
for mice deﬁcient in type I IFN responses. Differences in relative
sensitivity of the two viruses to a pre-established, IFN-α/β-induced
antiviral state in vitro were minor and did not appear to account for
the virulence differences in vivo. Finally, infection of normal mice
with BeAr436087 virus could protect from disease and reduce
mortality caused by FL93-939 infection, even if the BeAr436087
virus was given 8 h after FL93-939, consistent with the BeAr436087-
induced IFN-α/β acting to limit the virulence of FL93-939. From
these data, we infer that FL93-939 virulence in the mouse model is
primarily achieved by avoidance of IFN-α/β induction, while the
attenuation of BeAr436087 virus is associated with a robust type I
IFN induction and response.Fig. 1. Age-dependence of BeAr436087 and FL93-939 virulence in mice. Morbidity and mort
939. Age-dependence of mortality (A) and AST (B) in mice inoculated subcutaneously in th
survival (C) and average daily weight change (D) of 6-week-old mice infected in the hind fo
standard deviations.Results
Mouse-virulence of BeAr436087, but not FL93-939, is strongly
age-dependent
Most strains of EEEV are virulent for adult mice inoculated
subcutaneously (Aguilar et al., 2005; Vogel et al., 2005). However,
Weaver et al. identiﬁed a South American strain of EEEV
(BeAr436087) that was attenuated for adult mice (Aguilar et al.,
2005), but neurovirulent in 6-day-old mice inoculated intracerebrally
(Wang et al., 2007). We have previously demonstrated that age-
dependent attenuation of Sindbis virus (SINV) after subcutaneous
inoculation, occurs coincident with increasingly curtailed replication
in extraneural tissues between 5 and 11 d post-partum, associated
with transition from 100% to 0% mortality and suggestive of the
antiviral action of IFN-α/β (Ryman et al., 2007;Ryman et al., 2000). To
determine the relative attenuation of BeAr436087 compared with
SINV, we examined the age-dependence of BeAr436087 virulence
versus the adult mouse-virulent NA-EEEV strain, FL93-939. Beginning
with newborns, mice of increasing age were inoculated subcuta-
neously in the ventral thorax with equal doses of FL93-939 or
BeAr436087 and monitored for signs of morbidity and mortality. As
expected, FL93-939 caused severe disease and death in all ages of
mice, although the average survival time (AST) extended slightly with
increasing host development (Figs. 1A–C). BeAr436087 virus infection
was similarly virulent in mice 1-day-old through 2-week-old, but the
AST extended signiﬁcantly and mortality rates decreased between 2
and 4 weeks of age, such that all 4-week-old mice survived. Therefore,
while attenuated in older mice compared with FL93-939, BeAr436087
is signiﬁcantly more virulent than SINV.ality data from CD1 mice infected subcutaneously with 103 pfu of BeAr436087 or FL93-
e ventral thorax with BeAr436087 (hatched bar) or FL93-939 (black bar). Percentage
otpad with BeAr436087 (open circle) or FL93-939 (closed circle). Error bars represent
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exhibited minimal clinical sign of disease (Fig. 1C), but were
nevertheless protected from challenge with FL93-939 virus 3 weeks
later (data not shown), as previously observed (Wang et al., 2007).
Interestingly, when we examined morbidity in 6-week-old mice (Fig.
1D), the avirulent BeAr436087 virus was found to cause greater
weight loss than virulent FL93-939 virus in the early stages of
infection, 1–2 d post-infection (p.i.; pb0.01). For the related
alphavirus, Venezuelan equine encephalitis virus (VEEV), early weight
loss is typically associated with the so-called “lymphotrophic” stage of
disease (Charles et al., 2001; Gardner et al., 2008) and a proin-
ﬂammatory response (Grieder et al., 1997), whereas FL93-939
infection displays greatly reduced lymphotropism (Gardner et al.,
2008). Thus, we speculated that the tropism of BeAr436087 and FL93-
939 might differ, with a more pronounced lymphotropic phase in
BeAr436087 infection.
BeAr436087 disseminates and ampliﬁes more rapidly than FL93-939 in
adult mice
To investigate the mechanism(s) underlying the early morbidity,
as well as the ultimate attenuation of BeAr436087, we compared the
replication and dissemination of BeAr436087 in 6-week-old outbred
CD1 mice, an age at which BeAr436087 is attenuated regardless of
inoculation route while FL93-939 is uniformly fatal. Data for FL93-939
infection were previously published (Gardner et al., 2008), but
collected alongside the current experiments and, therefore, included
in ﬁgures for clarity. We examined lymphoid tissues including
draining lymph node (DLN) and spleen, mesenchymal tissues
including femur epiphyses, metaphyses and bone aspirate, and
brain, infection of which is associated with NA-EEEV-induced
mortality (Vogel et al., 2005; Gardner et al., 2008; Aguilar et al.,
2005; Wang et al., 2007). Overall, BeAr436087 replication wasFig. 2. Comparison of BeAr436087 and FL93-939 replication and dissemination. 6-week-old
circle) in each hind footpad. Mice were perfused with PBS–1% DCS prior to tissue harv
homogenates were determined by BHK-21 plaque titration: A) popliteal draining lymph n
aspirate (femur); F) brain. LD=limit of detection of the plaque assay and error bars represdistinctly different from that of FL93-939 (Fig. 2). Perhaps counter-
intuitively, attenuated BeAr436087 initially replicated to higher levels
than virulent FL93-939 in all tissues, suggesting that BeAr436087
exhibits higher ﬁtness for early disseminated replication in vivo.
Previously it was observed that NA-EEEV strains including FL93-
939 ampliﬁed poorly in the DLN and spleen (Vogel et al., 2005;
Gardner et al., 2008), which we attributed to inefﬁcient replication of
the virus in myeloid-lineage cells such as macrophages and DCs
(Gardner et al., 2008). Levels of BeAr436087 virus in the DLN
surpassed input inoculum titers within 6 h p.i. (Fig. 2A) while FL93-
939 barely exceeded input even at peak titer 18 h p.i. Furthermore,
peak BeAr436087 titers were approximately 100-fold higher than
FL93-939, suggestive that BeAr436087 was able to replicate more
efﬁciently either in similar cells or in a different cell-type in the DLN
than FL93-939.
Both viruses produced a serum viremia; however, BeAr436087
viremia was over 10-fold higher and slightly extended in duration
compared to FL93-939 (Fig. 2B). When dissemination of the two
viruses was compared (Figs. 2C–E), BeAr436087 virus was detected in
the spleen 6 h earlier than FL93-939, and BeAr436087 titers in the
spleen were dramatically higher than FL93-939 (N100-fold at 24 and
48 h p.i. and ∼100-fold at 72 h p.i.), suggesting that BeAr436087
replicates with considerably greater efﬁciency in lymphoid and
reticuloendothelial tissues. These data were consistent with the
ﬁndings of Aguilar et al. (2008a). Differences between the two viruses
were not as dramatic in the knee joint and bone aspirates, although
BeAr436087 replicated more rapidly and to higher peak titers (N10-
fold higher in both tissues; Figs. 2D and E).
Both viruses were detectable in the central nervous system (CNS)
by 24 h p.i (Fig. 2F), but, once again BeAr436087 virus loads were
higher than FL93-939 at early times. By 48 h p.i., however, clearance of
BeAr436087 from the brain was evident and this virus was
undetectable by 120 h p.i. In contrast, FL93-939 virus titers continuedCD1 mice were infected with 103 pfu of BeAr436087 (open circle) or FL93-939 (closed
esting, homogenization and mechanical disruption. Virus titers in serum and tissue
ode; B) serum; C) spleen; D) knee joint (femur epiphyses and metaphyses); E) bone
ent standard deviations.
Table 1
Mortality rates and average survival time of different mouse strains infected with EEEV.
Virus Mouse strain
CD1 CD1 C57BL/6 RAG1−/− 129 Sv/Ev IFNGR−/− IFNAR−/− IFNAGR−/− STAT1−/−
FL93-939 Percent mortality 100% 75% 100% 75% 100% 100% 100% 100%
AST (days) 5.0±0.7 7.0±2.5 5.9±1.1 6.1±0.9 4.9±0.8 2.4±0.5 2.4±0.5 2.4±0.3
BeAr436087 Percent mortality 0% 0% 0% 0% 0% 100% 100% 100%
AST (days) N/A N/A N/A N/A N/A 1.8±0.3 1.9±0.5 2.1±0.3
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were measured in BeAr436087-infected animals. These data imply
that, reﬂective of higher and earlier replication of BeAr436087 in
peripheral tissues, neuroinvasion occurs earlier. However,
BeAr436087 replication is curtailed, while that of FL93-939 is poorly
restrained, correlated with outcome.
IFN-α/β responses determine attenuation of BeAr436087 in 6-week-old
mice
To determine directly, the role of the innate immune response,
speciﬁcally the type I IFN response, versus the adaptive immune
response in the attenuation of BeAr436087 in comparison with FL93-
939, we tested virus virulence in a panel of mice deﬁcient in speciﬁc
components of both immune response arms (Table 1). In the absence
of functioning B and T cell activities, (RAG−/− mice), BeAr436087
remained avirulent, suggesting that these functions are not respon-
sible or required for the high degree of attenuation. FL93-939
exhibited a slightly decreased AST and increased mortality in these
mice versus C57BL/6 controls (at this dose mortality is less than 100%
in C57BL/6) suggesting some role for adaptive responses in control of
FL93-939 virulence. Shortened survival was primarily associated with
higher FL93-939 titers in the spinal cords and brains of moribund
RAG−/− mice (data not shown).
When we examined virulence in mice deﬁcient in IFN-γ signaling,
BeAr436087 infection did not result in mortality, similar to RAG−/−
mice, FL93-939-infected IFNGR−/− mice exhibited an increase in
mortality and decrease in AST suggestive of a minor role of the IFN-γ
pathway in protection from disease. In contrast, both viruses caused
100% mortality in mice deﬁcient in IFN-α/β signaling (IFNAR1−/−),
both IFN-α/β and IFN-γ signaling (IFNAGR−/−) or the STAT1
transcription factor (STAT1−/−; Table 1). Furthermore, mortality
occurred slightly more rapidly with BeAr436087 than FL93-939 in allFig. 3. Effect of type I IFN responses on BeAr436087 replication and dissemination. BHK cell
deﬁcient and control mice infected with 103 pfu of BeAr436087 in the hind footpad. Mice wer
disruption: A) 129 Sv/Ev (black bars), IFNAR1−/− (hatched bars), IFNAGR−/− (white bars)
were collected at 24 h p.i. LN=popliteal lymph node. Joint=knee joint. B) Mice were infecte
at 48 h p.i. Error bars represent standard deviations.three types of mice, although the differences were not highly
signiﬁcant (p=0.06 for IFNAR1−/−; p=0.07 for IFNAGR−/− and
p=0.20 for STAT1−/−). Thus, consistent with early titration data from
CD1 mice, BeAr436087 exhibits equal and in some cases superior
replication ﬁtness to that of FL93-939 in vivo and the attenuation of
BeAr436087 in adult mice is primarily attributable to the antiviral
effects of type I IFN.
To determine the effects of IFN-α/β signaling in the pathogenesis
of BeAr436087 in more detail, we examined the replication and
dissemination of the virus in the three types of mice with deﬁcits in
the IFN-α/β response (IFNAR1−/−, IFNAGR−/− and STAT1−/−
strains). Serum and perfused tissues were collected to titer virus at
24 h p.i. (Fig. 3), a time at which no mice would have succumbed to
infection, both BeAr436087 and FL93-939 have invaded the brain
and their replication is distinguishable in CD1 mice. Each of the IFN-
α/β signaling-defective mouse strains experienced higher replica-
tion of BeAr436087 than controls in all measured tissues and serum
(Fig. 3A), indicating that the effects of disruption of IFN-α/β
signaling upon mortality were correlated with a large increase in
virus growth. In more detailed titrations comparing serum titers of
STAT1−/− and 129 Sv/Ev control mice, the appearance of higher
replication in the STAT1−/− animals was not observed until 18 h p.i.
consistent with a requirement for induced IFN-α/β signaling for
protection in the immunocompetent mice (data not shown). Virus
titers in STAT1−/− mice were signiﬁcantly lower than those in
IFNAR1−/− and IFNAGR−/− mice in spleen, liver and brain (pb0.01),
indicating a STAT1-independent effect of IFN signaling in these tissues.
We also compared the replication of FL93-939 and BeAr436087 in the
brains of IFNAR1−/− mice to determine if BeAr436087 exhibited a
replication disadvantage versus FL93-939 in this tissue in the absence
of IFN-α/β responses. At 48 h p.i., a time at which replication of FL93-
939 had surpassed BeAr436087 in the brains of control mice (Figs. 1F
and 3B), BeAr436087 ampliﬁed to nearly 100-fold higher titer thanplaque titration of virus replication in various tissues and serum of 6–8 week-old IFN-
e perfused with PBS–1% DCS prior to tissue harvesting, homogenization andmechanical
and STAT1−/− (crosshatched bars) mice were infected with BeAr436087 and samples
d with BeAr436087 (hatched bars) or FL93-939 (black bars) and samples were collected
Fig. 4. Comparative replication of BeAr436087 and FL93-939 in relevant cell-types in vitro. Primary cultures of CD1-derived osteoblasts (A) and cortical neurons (B) were infected
with BeAr436087 (open circle) or FL93-939 (closed circle) and progeny virions were titered. Replication of BeAr436087 (C) and FL93-939 (D) in bone marrow-derived cDCs
generated from control 129 Sv/Ev (closed square) and IFNAR1−/− (open square) mice. All cells were infected at amoi of 0.1. LD=limit of detection for the plaque assay and error bars
represent standard deviations.
Fig. 5. Relative sensitivity of BeAr436087 and FL93-939 to IFN-α/β priming of primary
osteoblasts. Triplicate wells of primary osteoblasts generated from CD1 mice were
exposed to a range of IFN-α/β concentrations for 24 h prior to infection with SINV
(open square), BeAr436087 (open circle), FL93-939 (closed circle) or VEEV (closed
square) at a moi of 1 for each virus. Data are presented as a percentage of cells surviving
at 24 h p.i. versus the dose (IU/mL) of IFN-α/β used to prime.
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advantage.
BeAr436087 is not defective in replication in vitro compared with
FL93-939
Attenuation of BeAr436087 in mice does not appear to reﬂect a
generalized replication defect in comparison with FL93-939. To
examine the viruses' replication efﬁciency in more deﬁned conditions,
we infected primary cells representative of cell-types at initial sites of
virus replication (conventional myeloid dendritic cells [cDCs]), fueling
secondary viremia (osteoblasts) and associated with terminal disease
(cortical neurons) with BeAr436087 or FL93-939. Progeny virions
were titered by standard plaque assay. In primary osteoblasts and
neurons, the two viruses replicated similarly and at some times
BeAr436087 even produced higher titers than FL93-939 (Figs. 4A and
B). Neither virus replicated efﬁciently in bone marrow-derived cDCs
(Figs. 4C and D), or macrophages (data not shown). This is consistent
with our previously published results in which FL93-939 replicated
poorly in cultured myeloid-lineage cells even in the absence of IFN-α/
β signaling (Gardner et al., 2008). However, these results were
somewhat surprising for BeAr436087 since this virus grows to
relatively high titers in vivo in DLN and spleen. It is possible that
either the cells supporting BeAr436087 growth in lymphoid tissues
are of a different myeloid lineage from those derived by culture of
bone marrow or that there is a non-myeloid cell-type in these
lymphoid tissues that supports replication of BeAr436087 signiﬁ-
cantly better than FL93-939.
BeAr436087 and FL93-939 are equally sensitive to murine IFN-α/β
priming in vitro
As described above, osteoblasts are an important cell-type for
fueling of the serum viremia in mice infected with EEEV (Vogel et al.,
2005; Gardner et al., 2008; Wang et al., 2007). Furthermore, to
provide relative scale of sensitivity, we included in these studies VEEV
(strain ZPC738) and SINV (strain TR339) that have high and lowresistance, respectively, to the IFN-α/β-induced antiviral state in
murine cells (Ryman and Klimstra, 2008). Cells were pretreatedwith a
range of IFN-α/β concentrations, infected with viruses and subse-
quently observed for protection from cytopathic effect (CPE) at 24 h p.
i. (when 100% CPE was observed in unprimed controls for all virus
infections). As expected, VEEV was the least sensitive and SINV was
the most sensitive to IFN-α/β pretreatment (Fig. 5). BeAr436087 and
FL93-939 were restricted at similar concentrations of IFN-α/β used
for priming (50% CPE between 5 and10 international units [IU]/mL
IFN-α/β) and were intermediately sensitive between SINV and VEEV.
Similar results were observed in Swiss 3t3 ﬁbroblast cells (data not
shown). Together, these data suggest that induced IFN-α/β in vivo
would be similarly protective against BeAr436087 and FL93-939, since
Fig. 7. STAT1 phosphorylation in brains of BeAr436087-infected and FL93-939-infected
mice.Western blot detection of the abundance of STAT1 and its phosphorylation state at
24 or 48 h p.i. in lysates from whole brains of 6-week-old CD-1 mice infected
subcutaneously in the hind footpad with 103 pfu of BeAr436087 (BeAr) or FL93-939
(FL93). (+)=positive control inwhich 100,000 IU of IFN-α/βwas injected directly into
the brains of CD1 mice and whole brain lysates were harvested 30 min later.
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antiviral effects of murine IFN-α/β.
Systemic IFN-α/β is induced in BeAr436087-infected, but not
FL93-939-infected mice
We previously demonstrated that the extensive replication of
VEEV in DLN and spleen was associated with dramatically higher
levels of IFN-α/β in the serum compared with FL93-939 (Gardner et
al., 2008). To examine this parameter comparing FL93-939 and
BeAr436087, biological IFN-α/β activity assays were conducted on
serum samples at various times p.i. As previously reported (Gardner et
al., 2008), FL93-939 virus only produced detectable of IFN-α/β in
serum at 48 h p.i. and this was barely above the limit of detection of
the assay. In contrast, BeAr436087 induced high levels of IFN-α/β at
24 h p.i., that peaked at 48 h p.i at approximately 103.5 IU/mL, over
150-fold higher than in FL93-939 infected mice (Fig. 6). These data
reveal the possibility that systemic IFN-α/β induced in BeAr436087-
infected mice is contributing to their survival and leading to clearance
of the virus from CNS tissues.
We also examined systemic IFN-α/β in 2-week-old mice, an age in
which both viruses cause 100%mortality with similar AST. Only 48 h p.
i. was examined, because this was the time at which peak levels of
IFN-α/βwere induced in the 6-week-old mice. IFN-α/β levels similar
to the sera of the 2-week-old and 6-week-old mice infected with
BeAr436087; however, the 2-week-old mice infected with FL93-939
produced much higher levels of serum IFN-α/β than 6 week-old mice
which were comparable to mice infected with BeAr436087 (data not
shown). These data suggest that tropism of one or both viruses might
be altered in 2-week-old mice and that IFN-α/β responses are not
fully potentiated for protection of these mice.
BeAr436087 infection leads to STAT1 phosphorylation in the CNS, but
FL93-939 does not
To determine if the systemic IFN-α/β produced in the
BeAr436087-infected mice was capable of inducing an antiviral state
in the CNS, we infected CD1micewith either BeAr436087 or FL93-939
and, at 24 and 48 h p.i., harvested the brain for western blot analysis of
STAT1 phosphorylation status (Fig. 7). STAT1 is an IFN-α/β inducible
transcription factor, activated through phosphorylation by JAK1 and
Tyk2 kinases after IFN receptor signaling. Phosphorylated, dimerized
STAT1 molecules translocate to the nucleus to directly transactivate
IFN-inducible gene promoters (reviewed by van Boxel-Dezaire et al.,
2006). A distinct increase in phosphorylation of STAT1 was observed
at both times in the brains of BeAr436087 mice while the increase inFig. 6. Induction of systemic IFN-α/β in BeAr436087-infected versus FL93-939-infected
mice. Results of biological assay for detection of IFN-α/β in the serum of 6-week-old
CD1 mice infected with 103 pfu of FL93-939 (black bars) or BeAr436087 (white bars) in
the hind footpad. LD=limit of detection of the IFN-α/β assay and error bars represent
standard deviations.the brains of FL93-939-infected counterparts was minimal. Further-
more, BeAr436087 infection caused an increase in total STAT1
consistent with the effects of IFN-α/β upon the abundance of this
protein (van Boxel-Dezaire et al., 2006). Taken together, these data are
consistent with the idea that BeAr436087 infection induces greater
systemic IFN-α/β production than FL93-939 resulting in a more
effective antiviral state in the CNS, thereby attenuating neurovirulence
of the virus.
Priming of mice with BeAr436087 protects against FL93-939 disease
Weaver et al. found that avirulent BeAr436087 infection could
elicit an adaptive immune response in mice that protected against
FL93-939 challenge several weeks later (Wang et al., 2007),
presumably by eliciting neutralizing antibody. Since the viruses are
similarly sensitive to IFN-α/β priming, but BeAr436087 induces
systemic IFN-α/β production while FL93-939 does not, we hypothe-
sized that inoculation of mice with BeAr436087 would induce an
innate immune response that could protect against FL93-939
challenge. CD1 mice were inoculated subcutaneously in the rear
hind-limb footpad with BeAr436087 and challenged with FL93-939
either simultaneously, 8 or 24 h later in the ipsilateral or contralateral
footpad (Fig. 8). Infection of mice with BeAr436087 at either 24 or 8 h
prior to FL93-939 completely protected against disease and fatality
following FL93-939 challenge regardless of whether the viruses were
inoculated in the ipsilateral or contralateral footpad. Partial protection
was observed when the viruses were inoculated in the same or
opposite footpads simultaneously and even when BeAr436087 was
administered 8 h after FL93-939. Higher protection for BeAr436087
given 8 h after FL93 versus simultaneous administration appeared to
reﬂect experiment-to-experiment variation as the percentage of sur-
vivors was variable, although, the protective phenotype was consis-
tently reproducible. A small amount of protection even developed
when BeAr436087 was administered 24 h after FL93-939, but only if
given in the ipsilateral footpad. There is a possibility that viruses given
in the same footpad could compete for cell targets; however, the fact
that contralateral footpad administration was protective suggests that
BeAr436087 infection activated the innate immune system to
establish an antiviral state that was attenuating to FL93-939 disease,
consistent with the relative sensitivity of this virus to IFN-α/β in vitro.
Discussion
It is a commonly held belief that pathogenic viruses have evolved
mechanisms to subvert host antiviral defenses resulting in disease
Fig. 8. Rapid BeAr436087-mediated protection against FL93-939-induced mortality in CD1 mice. 6-week-old mice were untreated or inoculated with 103 pfu of BeAr436087
(“treatment” in the ﬁgure) either 24, 8 or 0 h prior to, or 8 or 24 h after, inoculation in the left hind footpad with 103 pfu of FL93-939. BeAr436087 inoculations were either the same
(ipsilateral) or opposite (contralateral) footpad as FL93-939. Data are presented as the percentage of mice surviving the FL93-939 infection at 21 d p.i.
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and replicate in myeloid-lineage cells at the site of inoculation and
appear to usurp their migratory capabilities to reach the DLN, an early
site of virus ampliﬁcation, and seed the initial serum viremia
(reviewed by Ryman and Klimstra, 2008). The ability of a closely-
related encephalitic alphavirus, VEEV, to replicate in lymphoid tissues
is positively associated with virulence in the mouse model and
reduced lymphotropism resulting from mutation is strongly asso-
ciated with attenuation (Grieder et al., 1995; MacDonald and
Johnston, 2000). During VEEV infection high systemic levels of
cytokines including IFN-α/β are elicited and yet the virus manages
to replicate efﬁciently and cause disease (Charles et al., 2001; Ryman
and Klimstra, 2008; Gardner et al., 2008). On the other hand, FL93-
939, representative of North American EEEV isolates, appears to
circumvent the IFN-α/β-mediated antiviral response by avoiding
infection of lymphoid tissues in general, and myeloid cells in
particular, and limiting systemic IFN-α/β production (Gardner et al.,
2008). As a direct extension of this observation, we now propose that
the capacity of avirulent EEEV strains such as BeAr436087 to replicate
efﬁciently within lymphoid tissues correlates with IFN-α/β induction
and attenuation of disease.
We found that the avirulent SA-EEEV BeAr436087 strain initially
replicated to higher titers in all infected tissues examined in 6-week-
old mice and neuroinvaded more rapidly than the virulent FL93-939
strain, indicating no basic defect in replication in vivo. However, as
infection progressed, BeAr436087 replication was cleared from the
brain while that of FL93-939 increased to the point the mice
succumbed to infection. Uniquely, BeAr436087 replicated much
more efﬁciently than FL93-939 in lymphoid tissues throughout
infection. These replication differences were associated with induc-
tion of high levels of serum IFN-α/β by BeAr436087 whereas FL93-
939 rarely induced detectable IFN-α/β above the limit of detection of
the assay, and systemic IFN-α/β induction after BeAr436087 infection
was associated with STAT1 phosphorylation in the brain. BeAr436087
did not exhibit a defect in replication in osteoblasts or neurons in vitro
and was similarly sensitive as FL93-939 after IFN-α/β priming of
primary osteoblasts or a ﬁbroblast cell line. While absence of T and B
cell activities did not render BeAr436087 virulent, when the capacity
to respond to IFN-α/β was removed as in the IFNAR1−/−mice,
BeAr436087 caused more rapid mortality than FL93-939 andreplicated to higher titers in the brain by 48 h p.i. Finally,
administration of BeAr436087 shortly before, simultaneous with or
shortly after FL93-939 inoculation, resulted in partial or complete
protection from fatal FL93-939 disease. These data provide strong
evidence that BeAr436087 attenuation is: i) determined by the
effectiveness of the type I IFN response; ii) associated with enhanced
control and clearance of replication from the brain versus FL93-939;
and iii) associated with IFN-α/β induction that results in STAT1
activation in the brain. Moreover, BeAr436087 infection can create an
environment in vivo that attenuates FL93-939 disease. We propose
that BeAr436087 attenuation in comparison with FL93-939 can, in
large part, be attributed to the virus' capacity to replicate efﬁciently in
lymphoid tissue leading to systemic IFN-α/β production, activation of
an antiviral state in the CNS and protection from lethal encephalitic
disease.
Another contributing factor in the attenuation of BeAr436087
might be differential sensitivity versus FL93-939 to the antiviral state
in IFN-α/β-primed cells. Previous work suggested that NA and SA
strains of EEEV differed in their sensitivity to human IFN-α and IFN-β
(Aguilar et al., 2005, 2008a). In contrast with these studies, we did not
detect signiﬁcant differences in sensitivity, which might indicate
species- or cell-type speciﬁcity of responses to IFN-α/β. However, we
have utilized primary cells derived from tissues infected by these
viruses in mice and found little difference in IFN-α/β sensitivity
between the two. Clearly, more detailed IFN-α/β sensitivity analyses
will be required to determine reasons for the different results.
Nonetheless, the fact that BeAr436087 induces high systemic levels
of IFN-α/β that activates STAT1 in the CNS, while FL93-939 does not,
implies an impact upon virulence. The idea that differences in
sensitivity to the antiviral state between FL93-939 and BeAr436087
may not be correlated with virulence is further supported by the fact
that administration to mice of the IFN-inducing double stranded RNA
mimic, poly (I:C), attenuated FL93-939 disease (Aguilar et al., 2005),
similar to our results with BeAr436087 co-infection. We have
considered that the difference in brain STAT1 phosphorylation
between mice infected with the two viruses is reﬂective of antagon-
ism of this pathway in FL93-939-infected cells. However, at 48 h p.i.
proteins from virus-infected cells represent a small fraction of total
material in the lysates and, furthermore, in separate experiments, we
determined that FL93-939 did not signiﬁcantly block STAT1
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Yin, W.B. Klimstra and K.D. Ryman, unpublished observations).
It has been proposed that New World alphaviruses prevent
production of IFN-α/β from infected cells by causing generalized
arrest of host transcription and translation (Aguilar et al., 2008b;
Garmashova et al., 2007). However, the induction of high levels of
serum IFN-α/β after VEEV infection contradicts this assertion in vivo;
although at least some serum IFN-α/β in VEEV-infected mice may
originate from uninfected, neighboring cells (Konopka et al., 2007).
Recently it was demonstrated that a deletion mutation in the EEEV
capsid that impaired transcriptional shutoff also greatly attenuated
the virus in vivo (Aguilar et al., 2007b, 2008b). Unfortunately, systemic
IFN-α/β responses were not measured in these studies so the
relationship of this attenuation mechanism to IFN responses in vivo
is unclear. It would be of interest to compare the host cell shutoff-
inducing capacity of BeAr436087 to that of FL93-939.
The underlying mechanism by which BeAr436087 replicates
efﬁciently in DLN and spleen is not known. Our results titering virus
produced by cultured cells and mouse tissues suggest that, in the
absence of induced IFN-α/β, BeAr436087 may have a slight growth
advantage over FL93-939 in multiple cell/tissue types. We demon-
strated previously that FL93-939, in contrast with SINV or VEEV, was
unable to replicate within myeloid-lineage cells in vitro or in vivo due
to the inability of the incoming genome to be efﬁciently translated and
that this was attributable to effects of sequences/structures in the 5′
and/or 3′ non-translated regions and/or translation control elements
in nsP1 (Gardner et al., 2008). We had expected that the higher titers
of BeAr436087 in lymphoid tissues would reﬂect increased capacity of
this virus to replicate in myeloid cells. However, BeAr436087, like
FL93-939, was essentially replication-defective in bone marrow-
derived cDCs and macrophages in vitro. It remains to be determined
whether or not the efﬁcient replication of BeAr436087 that is linked to
IFN-α/β induction in vivo is due to tissue-speciﬁc interaction with
speciﬁc cell subsets or higher numbers of infected cells in all tissues.
The fact that STAT1was not highly phosphorylated in the CNS of FL93-
939-infected mice, even though this virus replicated to higher levels
than BeAr436087, is suggestive that a subset of infected tissues are
involved in IFN-α/β induction by BeAr436087. However, wemust also
consider that antagonism of IFN induction in neurons could explain
the differential STAT1 phosphorylation. We feel that this is unlikely as
neither of the two viruses elicit IFN-α/β from cultured cortical
neurons due to rapid shutoff of host macromolecular synthesis (J. Yin,
C.L. Gardner, C.W. Burke, K.D. Ryman and W.B. Klimstra, unpublished
observations). Ultimately the answer to this question will come from
detailed examination of the targets of FL93-939 and BeAr436087
infection in mouse lymphoid tissues.
It is possible that these results may be broadly applicable to the
mechanisms of attenuation of SA-EEEV versus NA-EEEV strains in
humans. Aguilar et al. (2008a) came to the conclusion that activities
encoded by both structural and non-structural proteins were involved
in the virulence of the NA-EEEV viruses and that increased sensitivity
to human IFN-α/β of SA-EEEV strains may be one mechanism
contributing to their attenuation. We now add lymphoid tissue
replication resulting in high levels of systemic IFN-α/β induction by
SA-EEEV strains as another possible mechanism. The relative
contribution of IFN-α/β sensitivity versus induction to differences in
virulence is currently not known. Further testing of our hypothesis can
be achieved by examination of additional NA-EEEV and SA-EEEV
isolates.
Finally, we believe our ﬁndings have applicability to strategies for
both designing effective antiviral therapies and for design of a live-
attenuated vaccine against EEEV. Our data combined with that of
Aguilar et al. (2005) suggest that IFN-α/β administration or artiﬁcial
induction of IFN-α/β responses offers promise as a therapeutic
strategy during acute phase EEEV disease. The fact that BeAr436087
replicates very efﬁciently in lymphoid tissues suggests that it wouldalso make an effective alphavirus vaccine or delivery system for
heterologous antigens, supported by the ﬁndings of Weaver and
coworkers (Wang et al., 2007, 2008). Furthermore, the IFN-α/β
induction data indicate that this virus would elicit robust innate
immune responses that are critical to adjuvant effects of alphavirus
vectors (Thompson et al., 2006; Hidmark et al., 2006). Most
compelling, however, was the observation that in addition to use as
a prophylactic vaccine, BeAr436087 immunization could be used in
the event of a BWT attack as a post-exposure therapeutic agent.
Materials and methods
Cell lines
Baby hamster kidney (BHK)-21 and L929 murine ﬁbrosarcoma
cells were maintained in alpha minimum essential medium (αMEM)
and supplemented with 10% donor calf serum (DCS) and tryptose
phosphate broth, 0.25 mg/mL L-glutamine, 100 U/mL penicillin, and
0.05 mg/mL streptomycin. Swiss 3t3 murine ﬁbroblast cells were
maintained inαMEM and supplementedwith 10% DCS, 0.25mg/mL L-
glutamine, 100 U/mL penicillin, and 0.05 mg/mL streptomycin.
Mice
Outbred CD1 (Charles River Laboratories), 129 Sv/Ev (Taconic
Laboratories) and C57BL/6 (Jackson Laboratories) mice were pur-
chased. Mice deﬁcient in IFN-α/β receptor (IFNAR1−/−), IFN-γ
(IFNGR−/−), IFN-α/β/γ (IFNAGR−/−), STAT1 (STAT1−/−) or recom-
binase activating gene 1 (RAG-1; RAG−/−) mice were bred in-house.
All mice were housed in the Animal Resource Center at LSUHSC-S
under speciﬁc pathogen-free conditions. CD1 mice were used at
various ages as speciﬁed in ﬁgure legends. Other mouse strains were
used at 6–8 weeks of age. All experiments were conducted in
accordance with the guidelines of the LSUHSC-S Institutional Animal
Care and Use Committee in the Biosafety Level (BSL)-3 facilities.
Primary cell cultures
cDC cultures were derived from bone marrow and cultured, as
previously described (Gardner et al., 2008). Brieﬂy, bone marrow was
aspirated from femurs and tibias of mice and plated for 1 h (37 °C; 5%
CO2) to allow macrophage contaminates to adhere, after which the
non-adherent cDC progenitors were removed and cultured. The cDCs
were cultured in RPMI 1640 medium, supplemented with 10% fetal
bovine serum (FBS), 1% nonessential amino acids, 1 mM sodium
pyruvate, 5 mM HEPES buffer, 50 μM β-mercaptoethanol, 10 ng/mL
granulocyte–macrophage colony stimulating factor, and 10 ng/mL IL-
4 (Peprotech, Rocky Hill, NJ). After 7 d in culture, non-adherent cDCs
were pelleted, counted and resuspended in supplementedmedium for
infection.
Primary murine osteoblasts were generated from calvaria of 3–5-
day-old sucking mice as previously described (Gardner et al., 2008).
Brieﬂy, the calvaria were removed and gently scraped until white
before digesting three times in αMEM containing 0.05% trypsin–EDTA
and 10 mg/mL collagenase P. The cells were cultured for 5 d in αMEM
with 15% FBS, 100 U/mL penicillin and 0.05 mg/mL streptomycin to
allow outgrowth of osteoblasts from calvaria. Osteoblasts were then
trypsinized, strained to remove any remaining bone fragments and
seeded into 100 mm culture dishes. Once conﬂuent, the osteoblasts
were trypsinized, counted and seeded appropriately for experiments.
Primary neurons were generated from embryo cortices at 13–16 d
gestation, essentially as described (Samuel et al., 2006). Brieﬂy, the
cortices were digested in Hanks balanced salt solution containing
papain (1 mg/mL), DNase I (50 μg/mL), L-cysteine (0.2 mg/mL),
calcium chloride (1.5 mM), and EDTA (0.5 mM). Poly-D-lysine (PLD)-
coated plates were prepared by incubating 30 μg/mL PLD in the 24-
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coated 24-well plates at 2×105 cells per well and cultured in
neurobasal medium with 2% B27 additive (Invitrogen), 0.5 mM
glutamine and 20 μg/mL gentamicin. Cells were used after 6–7 d of
culture.
Viruses
cDNA clones for NA-EEEV strain FL93-939 (Aguilar et al., 2008a),
SA-EEEV strain BeAr436087 (Aguilar et al., 2008a) VEEV strain ZPC738
(Anishchenko et al., 2004), and SINV strain TR339 (Klimstra et al.,
1998) have been described previously. FL93-939, BeAr436087, and
ZPC738 cDNA clones were generously provided by Dr. Scott Weaver
(University of Texas Medical Branch, Galveston, TX). Brieﬂy, capped
infectious viral RNAs were generated by in vitro transcription
(mMessage mMachine, Ambion) from linearized cDNA plasmid
templates. The RNA was then electroporated into BHK-21 cells and
virus particles were harvested from the supernatant ∼24 h after
electroporation when CPE was evident. Cell debris was clariﬁed by
centrifugation and single-use virus aliquots were stored at −80 °C.
Virus stocks were titered by standard BHK-21 cell plaque assay and
titers were expressed as pfu/mL.
Mortality and pathogenesis studies
Virus inocula of FL93-939 or BeAr436087 containing 103 pfu in a
10 μL volume (1×105 pfu/mL) were administered subcutaneously in
the each rear footpad using a 27-gauge needle and 100 μL gas-tight
Hamilton syringe. Mock-infected mice received 10 μL PBS–1% DCS by
the same route. Virus-infected and mock-infected mice were
observed at 24 h intervals and weighed where appropriate. ASTs
and percent mortality were calculated. Mouse mortality curves were
compared using a Mantel–Cox log rank test with GraphPad Prism
software. Titer and weight differences were compared with a one-
tailed Student's t test for samples of equal variance using GraphPad
Prism software.
At predetermined intervals p.i., groups of threemice per treatment
were sacriﬁced under isoﬂurane-anesthesia and blood was collected
by cardiac puncture. Serum was separated from whole blood using
microtainer tubes (Becton-Dickinson) and stored in single-use
aliquots at −80 °C. Mice were then perfused with PBS–1% DCS for
10 min at 7 mL/min to ﬂush blood-borne virus. Tissues were
harvested into preweighed eppendorf tubes and homogenized in
9 volumes of PBS–1% DCS. Supernatants were assayed for virus by
standard plaque assay, expressed as pfu/DLN, mL or g.
Virus growth curves
Adherent cells were infected in 24-well plates at a moi of 1 pfu/cell
or 0.1 pfu/cell, as indicated in the ﬁgure legends. Virus was incubated
for 1 h at 37 °C, then cells were washed three times with PBS–1% DCS
diluent, appropriate medium was replaced and cells were incubated
(37 °C; 5% CO2). Non-adherent cDCs were infected in suspension in V-
bottom 96-well plates at the desired moi (37 °C; 1 h) and washed
three times in PBS–1% DCS by pelleting and resuspension. Cells were
resuspended in cDC culture media and seeded into 24-well plates. For
virus growth curves, supernatants were harvested at 0 h p.i. and
subsequent time-points for titration by standard plaque assay on BHK-
21 cells.
IFN-α/β analyses
Serum IFN-α/β was measured by standard biological assay on
L929 cells as described previously (Trgovcich et al., 1996), using
recombinant IFN-α/β as a standard and encephalomyocarditis virus
(EMCV) as the indicator of protection. Concentration of IFN-α/β wasdetermined by the dilution of IFN-α/β needed to cause 50% protection
from EMCV CPE. Levels of IFN-α/β were expressed as IU/mL.
IFN-α/β sensitivity assay
Primary murine osteoblasts or Swiss 3t3 cells in a 24-well plate
were treated with different concentrations of recombinant IFN-α/β
for 24 h, infected at an moi of 1 for 1 h (37 °C; 5% CO2), then washed
three times in PBS–1% DCS and appropriate media was added. The
cells were scored for percentage of CPE by 24 h p.i.
STAT1 in tissue lysates
CD1 mice were infected with 103 pfu subcutaneously in both rear
footpads with either FL93-939 or BeAr436087 and 24 and 48 h p.i.
brains were harvested and homogenized in 800 μL of lysis buffer
containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 10%
glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 2 μg/mL aprotinin,
5 μg/mL leupeptin, 5 μg/mL pepstatin, and phosphatase inhibitor
cocktails I and II (Sigma). Homogenized tissues were clariﬁed by
centrifugation (20,000×g, 10min, 4 °C) and protein concentrationwas
determined using BioRad protein assay. One hundred μg of protein
was separated on an 8% SDS-PAGE gel and transferred onto a
nitrocellulose membrane (BioRad). Membranes were blocked for 1 h
in 5% skim milk containing TBS/0.1% Tween 20 (TBST). The
membranes were incubated with primary antibody to p-Tyr701
STAT1 (Cell Signaling), total STAT1 (M-22; Santa Cruz), or β-actin
(Chemicon), in TBST with 3% BSA at 4 °C. Membranes were washed
with TBST and incubated with HRP-conjugated secondary antibody
(Zymed) in TBST with 2% skimmed milk. The ECL-Plus chemilumines-
cence system (Amersham) was used to develop the membranes.
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